US Patent

US10722522 — Dosing regimen for sedation with CNS 7056 (remimazolam)

Method of Use · Assigned to Paion UK Ltd · Expires 2031-11-07 · 5y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a dosing regimen for sedation using the benzodiazepine CNS 7056 (remimazolam) in combination with an opioid, specifically fentanyl.

USPTO Abstract

The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.

Drugs covered by this patent

remimazolam-besylate (REMIMAZOLAM BESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2968`	—	remimazolam-besylate

Patent Metadata

Patent number: US10722522
Jurisdiction: US
Classification: Method of Use
Expires: 2031-11-07
Drug substance claim: No
Drug product claim: No
Assignee: Paion UK Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.